– USA, MA – Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and certain inflammatory diseases, today announced the appointment of Dr. Todd C. Brady to the Company’s Board of Directors, effective July 28, 2016. Dr. Brady currently serves as Chief Executive Officer, President and Director of Aldeyra Therapeutics (Nasdaq:ALDX), a developer of drugs for the treatment of inflammation and inborn errors of metabolism.
“Dr. Brady brings to the Spring Bank Board of Directors a wealth of experience across the full spectrum of drug development and biopharmaceutical management. We look forward to his contributions as we continue to advance our lead compound, SB 9200, through Phase 2 development for the treatment of Hepatitis B,” said Martin Driscoll, Chairman, President and Chief Executive Officer of Spring Bank. “His insights will also be invaluable in relation to our plans to explore and pursue SB 9200 in other viral indications and advance our earlier stage compounds in the areas of inflammation and oncology.”
“Chronic Hepatitis B is a serious viral disease with a sizable global patient prevalence that, if left unchecked, can cause inflammation and severe damage to the liver,” commented Dr. Brady. “Many Hepatitis B patients show no symptoms until signs of liver damage appear, which speaks to the urgent need for a functional cure. I am encouraged by the pre-clinical and clinical data generated to date for SB 9200, and I look forward to working with Marty, the rest of the Spring Bank leadership team, and my fellow Board members to guide the Company through its next phase of growth.”
Dr. Brady was appointed President and Chief Executive Officer of Aldeyra Therapeutics in 2012, having been a member of the Board of Directors since 2005. Dr. Brady also served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, in 2013. Prior to joining the firm as a Principal in 2004 Dr. Brady held senior leadership positions at Aderis Pharmaceuticals, Inc., Xanthus Life Sciences, Inc., and Phenome Sciences. Dr. Brady also serves on the Board of Directors of Oncobiologics, Inc. and Evoke Pharma, Inc., both of which are publicly traded biotechnology companies, as well as a number of privately-held biotechnology companies. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
